Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 11/20 | 0.41 |
| ▸ | AURKA | O14965 | 2/20 | 0.39 |
| ▸ | KDR | P35968 | 2/20 | 0.39 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.39 |
| ▸ | PTGES | O14684 | 2/20 | 0.38 |
| ▸ | SCN2A | Q99250 | 2/20 | 0.37 |
| ▸ | HRH1 | P35367 | 1/20 | 0.37 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3798446 | 0.90 | TRPA1 (0.44) | DGAT1AURKAKDRERBB2PTGES | |
| SCHEMBL3795873 | 0.89 | PTGES (0.49) | DGAT1PTGES | |
| SCHEMBL11251610 | 0.79 | DGAT1 (0.37) | DGAT1AURKAKDRERBB2 | |
| SCHEMBL23847031 | 0.77 | TSHR (0.41) | DGAT1AURKAKDRERBB2 | |
| SCHEMBL27031612 | 0.76 | EGLN2 (0.35) | DGAT1 | |
| SCHEMBL3797673 | 0.76 | JAK2 (0.42) | DGAT1AURKAKDRERBB2PTGES | |
| SCHEMBL3584568 | 0.74 | SCN2A (0.58) | DGAT1AURKAKDRERBB2SCN2A | |
| SCHEMBL17868458 | 0.73 | DGAT1 (0.50) | DGAT1SCN2A | |
| SCHEMBL25174438 | 0.71 | SCN2A (0.72) | SCN2AHRH1HRH4 | |
| SCHEMBL30151211 | 0.70 | NPY5R (0.54) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230174523-A1 | BENZENESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF | AMATHUS THERAPEUTICS, INC. (US) | 2023-06-08 | — | — | US | disclosed |
| US-20230174523-A1 | BENZENESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF | AMATHUS THERAPEUTICS, INC. (US) | 2023-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230174523-A1 | BENZENESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF | TRAP1, PINK1, TP53BP1 | DGAT1 3633/4885AURKA 3307/4885KDR 2575/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.